Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites

Payman Zamani, Benjamin French, Jeffrey A. Brandimarto, Paschalis Thomas Doulias, Ali Javaheri, Julio A. Chirinos, Kenneth B. Margulies, Raymond R. Townsend, Nancy K Sweitzer, James C. Fang, Harry Ischiropoulos, Thomas P. Cappola

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Endothelial function may be deranged in heart failure with preserved ejection fraction (HFpEF). Serum NO-derived metabolites (NOm) might provide a biochemical surrogate of endothelial function in patients with heart failure (HF). We measured serum NOm in 415 participants in the Penn HF Study. Participants with HFpEF (n = 82) and those whose EF had recovered (Recovered-HF, n = 125) were matched 1:1 to heart failure with reduced ejection fraction (HFrEF) participants based on age, gender, race, tobacco use, and eGFR. Serum NOm levels were quantified after chemical reduction coupled with gas-phase chemiluminescence detection. After adjustment for matching covariates and BMI, HFpEF (34.5 μM; interquartile range [IQR] 25.0, 51.5) participants had lower NOm levels than HFrEF (41.0 μM; IQR 28.3, 58.0; ratio of HFpEF:HFrEF 0.82, 95% confidence interval [CI] 0.67 to 0.99; p = 0.04), which further decreased when adjusted for covariates that affect endothelial function (ratio 0.79, 95% CI 0.65 to 0.98; p = 0.03). There were no differences between HFrEF (34.0; IQR 25.3, 49.0) and matched Recovered-HF (36.0 μM; IQR 25.0, 55.0) or HFpEF and Recovered-HF. Age (+21%/10-year increase, p <0.001) and black race (−28%, p = 0.03) associated with NOm in HFpEF, whereas age (+11%/10-year increase, p = 0.03), current tobacco use (+67%, p = 0.01), and eGFR (p = 0.01) associated with NOm in Recovered-HF. In conclusion, HFpEF participants have reduced NOm compared with HFrEF in this matched cohort. This might suggest either compromised endothelial function or poor dietary intake. Black race was associated with lower NOm in HFpEF.

Original languageEnglish (US)
Pages (from-to)1855-1860
Number of pages6
JournalAmerican Journal of Cardiology
Volume118
Issue number12
DOIs
StatePublished - Dec 15 2016

Fingerprint

Nitric Oxide
Heart Failure
Tobacco Use
Serum
Confidence Intervals
Luminescence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Zamani, P., French, B., Brandimarto, J. A., Doulias, P. T., Javaheri, A., Chirinos, J. A., ... Cappola, T. P. (2016). Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. American Journal of Cardiology, 118(12), 1855-1860. https://doi.org/10.1016/j.amjcard.2016.08.077

Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. / Zamani, Payman; French, Benjamin; Brandimarto, Jeffrey A.; Doulias, Paschalis Thomas; Javaheri, Ali; Chirinos, Julio A.; Margulies, Kenneth B.; Townsend, Raymond R.; Sweitzer, Nancy K; Fang, James C.; Ischiropoulos, Harry; Cappola, Thomas P.

In: American Journal of Cardiology, Vol. 118, No. 12, 15.12.2016, p. 1855-1860.

Research output: Contribution to journalArticle

Zamani, P, French, B, Brandimarto, JA, Doulias, PT, Javaheri, A, Chirinos, JA, Margulies, KB, Townsend, RR, Sweitzer, NK, Fang, JC, Ischiropoulos, H & Cappola, TP 2016, 'Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites', American Journal of Cardiology, vol. 118, no. 12, pp. 1855-1860. https://doi.org/10.1016/j.amjcard.2016.08.077
Zamani P, French B, Brandimarto JA, Doulias PT, Javaheri A, Chirinos JA et al. Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. American Journal of Cardiology. 2016 Dec 15;118(12):1855-1860. https://doi.org/10.1016/j.amjcard.2016.08.077
Zamani, Payman ; French, Benjamin ; Brandimarto, Jeffrey A. ; Doulias, Paschalis Thomas ; Javaheri, Ali ; Chirinos, Julio A. ; Margulies, Kenneth B. ; Townsend, Raymond R. ; Sweitzer, Nancy K ; Fang, James C. ; Ischiropoulos, Harry ; Cappola, Thomas P. / Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. In: American Journal of Cardiology. 2016 ; Vol. 118, No. 12. pp. 1855-1860.
@article{d1f6c519c9ae41f2bae7fbf3616b323b,
title = "Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites",
abstract = "Endothelial function may be deranged in heart failure with preserved ejection fraction (HFpEF). Serum NO-derived metabolites (NOm) might provide a biochemical surrogate of endothelial function in patients with heart failure (HF). We measured serum NOm in 415 participants in the Penn HF Study. Participants with HFpEF (n = 82) and those whose EF had recovered (Recovered-HF, n = 125) were matched 1:1 to heart failure with reduced ejection fraction (HFrEF) participants based on age, gender, race, tobacco use, and eGFR. Serum NOm levels were quantified after chemical reduction coupled with gas-phase chemiluminescence detection. After adjustment for matching covariates and BMI, HFpEF (34.5 μM; interquartile range [IQR] 25.0, 51.5) participants had lower NOm levels than HFrEF (41.0 μM; IQR 28.3, 58.0; ratio of HFpEF:HFrEF 0.82, 95{\%} confidence interval [CI] 0.67 to 0.99; p = 0.04), which further decreased when adjusted for covariates that affect endothelial function (ratio 0.79, 95{\%} CI 0.65 to 0.98; p = 0.03). There were no differences between HFrEF (34.0; IQR 25.3, 49.0) and matched Recovered-HF (36.0 μM; IQR 25.0, 55.0) or HFpEF and Recovered-HF. Age (+21{\%}/10-year increase, p <0.001) and black race (−28{\%}, p = 0.03) associated with NOm in HFpEF, whereas age (+11{\%}/10-year increase, p = 0.03), current tobacco use (+67{\%}, p = 0.01), and eGFR (p = 0.01) associated with NOm in Recovered-HF. In conclusion, HFpEF participants have reduced NOm compared with HFrEF in this matched cohort. This might suggest either compromised endothelial function or poor dietary intake. Black race was associated with lower NOm in HFpEF.",
author = "Payman Zamani and Benjamin French and Brandimarto, {Jeffrey A.} and Doulias, {Paschalis Thomas} and Ali Javaheri and Chirinos, {Julio A.} and Margulies, {Kenneth B.} and Townsend, {Raymond R.} and Sweitzer, {Nancy K} and Fang, {James C.} and Harry Ischiropoulos and Cappola, {Thomas P.}",
year = "2016",
month = "12",
day = "15",
doi = "10.1016/j.amjcard.2016.08.077",
language = "English (US)",
volume = "118",
pages = "1855--1860",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites

AU - Zamani, Payman

AU - French, Benjamin

AU - Brandimarto, Jeffrey A.

AU - Doulias, Paschalis Thomas

AU - Javaheri, Ali

AU - Chirinos, Julio A.

AU - Margulies, Kenneth B.

AU - Townsend, Raymond R.

AU - Sweitzer, Nancy K

AU - Fang, James C.

AU - Ischiropoulos, Harry

AU - Cappola, Thomas P.

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Endothelial function may be deranged in heart failure with preserved ejection fraction (HFpEF). Serum NO-derived metabolites (NOm) might provide a biochemical surrogate of endothelial function in patients with heart failure (HF). We measured serum NOm in 415 participants in the Penn HF Study. Participants with HFpEF (n = 82) and those whose EF had recovered (Recovered-HF, n = 125) were matched 1:1 to heart failure with reduced ejection fraction (HFrEF) participants based on age, gender, race, tobacco use, and eGFR. Serum NOm levels were quantified after chemical reduction coupled with gas-phase chemiluminescence detection. After adjustment for matching covariates and BMI, HFpEF (34.5 μM; interquartile range [IQR] 25.0, 51.5) participants had lower NOm levels than HFrEF (41.0 μM; IQR 28.3, 58.0; ratio of HFpEF:HFrEF 0.82, 95% confidence interval [CI] 0.67 to 0.99; p = 0.04), which further decreased when adjusted for covariates that affect endothelial function (ratio 0.79, 95% CI 0.65 to 0.98; p = 0.03). There were no differences between HFrEF (34.0; IQR 25.3, 49.0) and matched Recovered-HF (36.0 μM; IQR 25.0, 55.0) or HFpEF and Recovered-HF. Age (+21%/10-year increase, p <0.001) and black race (−28%, p = 0.03) associated with NOm in HFpEF, whereas age (+11%/10-year increase, p = 0.03), current tobacco use (+67%, p = 0.01), and eGFR (p = 0.01) associated with NOm in Recovered-HF. In conclusion, HFpEF participants have reduced NOm compared with HFrEF in this matched cohort. This might suggest either compromised endothelial function or poor dietary intake. Black race was associated with lower NOm in HFpEF.

AB - Endothelial function may be deranged in heart failure with preserved ejection fraction (HFpEF). Serum NO-derived metabolites (NOm) might provide a biochemical surrogate of endothelial function in patients with heart failure (HF). We measured serum NOm in 415 participants in the Penn HF Study. Participants with HFpEF (n = 82) and those whose EF had recovered (Recovered-HF, n = 125) were matched 1:1 to heart failure with reduced ejection fraction (HFrEF) participants based on age, gender, race, tobacco use, and eGFR. Serum NOm levels were quantified after chemical reduction coupled with gas-phase chemiluminescence detection. After adjustment for matching covariates and BMI, HFpEF (34.5 μM; interquartile range [IQR] 25.0, 51.5) participants had lower NOm levels than HFrEF (41.0 μM; IQR 28.3, 58.0; ratio of HFpEF:HFrEF 0.82, 95% confidence interval [CI] 0.67 to 0.99; p = 0.04), which further decreased when adjusted for covariates that affect endothelial function (ratio 0.79, 95% CI 0.65 to 0.98; p = 0.03). There were no differences between HFrEF (34.0; IQR 25.3, 49.0) and matched Recovered-HF (36.0 μM; IQR 25.0, 55.0) or HFpEF and Recovered-HF. Age (+21%/10-year increase, p <0.001) and black race (−28%, p = 0.03) associated with NOm in HFpEF, whereas age (+11%/10-year increase, p = 0.03), current tobacco use (+67%, p = 0.01), and eGFR (p = 0.01) associated with NOm in Recovered-HF. In conclusion, HFpEF participants have reduced NOm compared with HFrEF in this matched cohort. This might suggest either compromised endothelial function or poor dietary intake. Black race was associated with lower NOm in HFpEF.

UR - http://www.scopus.com/inward/record.url?scp=84998880867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998880867&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2016.08.077

DO - 10.1016/j.amjcard.2016.08.077

M3 - Article

VL - 118

SP - 1855

EP - 1860

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -